6 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 39.5% per year over the past 5 years.
Operating margin has contracted, at -77.0% in the latest year.
Financial health
Total debt ($1.1B) exceeds cash ($311M); net debt is $749M.
The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$319M
-$289M
11.9%
-77.0%
-$451M
$1.1B
$311M
2024
$511M
-$1.4B
23.7%
-27.8%
-$52M
—
$836M
2023
$502M
-$246M
24.6%
1.8%
$49M
—
$50M
2022
$640M
-$2.1B
1.3%
-329.5%
-$179M
—
$16M
2021
$544M
$47M
43.9%
24.2%
-$57M
—
$118M
2020
$60M
-$12M
15.6%
-10.5%
-$24M
—
—
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$115M
-$347M
26.1%
-269.4%
-$139M
$2.1B
$1.0B
Dec '25
$80M
$214M
26.0%
-149.5%
-$122M
$1.1B
$311M
Sep '25
$81M
-$144M
4.8%
-67.6%
-$113M
—
$453M
Jun '25
$79M
-$937M
6.4%
-33.4%
-$87M
—
$581M
Mar '25
$80M
$576M
10.3%
-59.1%
-$129M
—
$698M
Dec '24
$95M
-$388M
5.0%
-171.3%
-$15M
—
$836M
Sep '24
$95M
-$455M
-0.2%
-43.2%
-$25M
—
$253M
Jun '24
$141M
-$902M
27.5%
-64.3%
-$2M
—
$96M
Mar '24
$179M
$211M
43.3%
30.8%
-$10M
—
$98M
Dec '23
$142M
-$196M
27.7%
2.8%
$10M
—
$50M
Sep '23
$113M
-$41M
13.7%
-10.7%
$3M
—
$42M
Jun '23
$127M
-$9M
29.1%
7.5%
$18M
—
$58M
Mar '23
$121M
-$388000
26.3%
6.3%
$18M
—
$47M
Dec '22
$121M
-$435M
-39.0%
-524.6%
-$24M
—
$16M
Sep '22
$163M
-$435M
-16.7%
-246.9%
-$57M
—
$30M
Jun '22
$164M
-$810M
7.8%
-637.5%
$40M
—
$129M
Mar '22
$193M
-$466M
36.4%
-13.9%
-$137M
—
$96M
Dec '21
$302M
-$13M
46.8%
-0.3%
$115M
—
$118M
Sep '21
$113M
-$19M
51.6%
-2.2%
-$77M
—
$2M
Jun '21
$75M
-$6M
32.6%
-1.9%
-$28M
—
$2M
Valuation over time
How the market has priced CORZ against its own fundamentals since 2024-01 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-sales ratio has risen from 1.9× (Jan '24) to 27.2× (Jun '26).
Price / sales (P/S)
P/S
Frequently asked questions
Is CORZ growing its revenue and profit?
Over the past 5 years, Core Scientific, Inc./Tx's revenue has grown 39.5% per year. These are computed facts, not advice.
How much debt does CORZ have?
As of FY2025, Core Scientific, Inc./Tx reported $1.1B of total debt against $311M of cash.
What is CORZ's profit margin?
In FY2025, gross margin was 11.9%, operating margin -77.0%, and net margin -90.5%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.